Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05342454 · ClinicalTrials.gov registry record

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

A clinical trial of Brain Tumor, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
1,720
Enrollment target
1
Study location

NCT05342454: Recruiting study of Brain Tumor, sponsored by M.D. Anderson Cancer Center.

NCT05342454 is a study of Brain Tumor that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,720 participants, above the 257-participant average among 69 other Brain Tumor trials with a reported enrollment target (569% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05342454, a study of Brain Tumor, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
1,720 participants
Enrollment target
1
Study location

Study Summary

Our preliminary work demonstrates that an integrated fMRI software solution, incorporating tb-fMRI, rs-fMRI, and CVR mapping, is clinically feasible and helps clinicians plan brain tumor resection. We have developed a novel automated seed selection method that can accurately map language networks from rs-fMRI. We hypothesize that our innovative approach to enhance, optimize, and validate our preliminary software and integrate it with an established fMRI platform will create robust solutions for clinical RSN and CVR mapping. Partnering with NordicNeuroLab (NNL) will leverage the professional software development by a seasoned commercial MRI software producer in coordination with leading clinical and research experts at MD Anderson. The research will be conducted through three specific aims: 1. Develop a clinical software platform for mapping RSNs and determine optimized workflow for presurgical localization of eloquent areas. 2. Develop a clinical software platform for mapping CVR and determine optimized workflow for identifying and visualizing brain areas with potential false-negative fMRI results. 3. Test and validate RSN and CVR mapping software in patients undergoing neurosurgery.

Conditions Studied

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 1,720 participants
Start Date 2022-05-23
Est. Completion 2026-11-30
M.D. Anderson Cancer Center

2,692 total trials

What NCT05342454 shows while recruiting

NCT05342454 is an observational study that tracks outcomes without assigning an intervention. Its 1,720 participants enrollment target places it among the larger protocols in the corpus, above the 257-participant average among 69 other Brain Tumor trials with a reported enrollment target (569% higher).

The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 0 interventions.

NCT05342454 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05342454 about?

NCT05342454 is a clinical study titled "A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain". Our preliminary work demonstrates that an integrated fMRI software solution, incorporating tb-fMRI, rs-fMRI, and CVR mapping, is clinically feasible and helps clinicians plan brain tumor resection. We have developed a novel automated seed selection method that can accurately map language networks fr...

What is the current status of trial NCT05342454?

This trial is currently recruiting. The enrollment target is 1,720 participants. The study started on 2022-05-23. Estimated completion is 2026-11-30.

What conditions does trial NCT05342454 study?

This clinical trial studies the following conditions: Brain Tumor.

Who is sponsoring clinical trial NCT05342454?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05342454 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05342454's enrollment target sits among peer trials

1,720 2nd of 69 the highest of 69 other Brain Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06898034 · 1,725 participants

    Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage

  • NCT04291612 · 1,715 participants

    Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

  • NCT05303636 · 1,710 participants · Phase 4

    LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

  • NCT06413420 · 1,731 participants

    SUNOSI® (Solriamfetol) Pregnancy Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05342454, the US trial registry maintained by the National Library of Medicine. NCT05342454 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.